Novo Nordisk's $1.1 Billion Deal to Expand Cardiovascular Pipeline
TL;DR Summary
Novo Nordisk has agreed to acquire Cardior Pharmaceuticals for up to $1.1 billion in a move to expand its cardiovascular pipeline, aligning with its focus on diabetes and weight-loss therapies. The deal includes Cardior's lead compound CDR132L, currently in Phase II trials for heart failure, with plans to start a second Phase II trial for cardiac hypertrophy. The acquisition is expected to close in the second quarter of 2024 and will not impact Novo's 2024 operating profit guidance.
Topics:business#acquisition#business-healthcare#cardior-pharmaceuticals#cardiovascular-disease#clinical-trials#novo-nordisk
- Novo Nordisk strikes deal worth up to $1.1 bln to expand cardio business Reuters
- Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease BioSpace
- Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals The Wall Street Journal
- Novo Nordisk to buy Cardior, building up pipeline of heart drugs STAT
- Novo Nordisk targets heart disease in $1.1 billion deal MarketWatch
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
78%
353 → 78 words
Want the full story? Read the original article
Read on Reuters